DNMT3A and coronary artery disorder: This multicenter study randomized approximately 28 individuals with known coronary artery disease and TET2 or DNMT3a CHIP to different combinations of DFV890, MAS825, and placebo, administered for 12 weeks, with a 30-day follow up.